Board for and getting consulting fees, charges for expert testimony, and fees for participation in speakers’ bureaus from Bristol-Myers Squibb; Dr. van den Eertwegh, getting consulting fees from and serving on a board for Bristol-Myers Squibb; Dr. Lutzky, getting consulting costs and honoraria from Bristol-Myers Squibb; Dr. Lorigan, getting consulting charges from Bristol-Myers Squibb; Dr. Hogg, serving on a board for Bristol-Myers Squibb (pending); Dr. Ottensmeier, getting honoraria and grant funding from Bristol-Myers Squibb; Dr. Lebb? serving on a board for Bristol-Myers Squibb; Dr. Wolchok, serving on a board for Bristol-Myers Squibb; Dr. J.S. Weber, getting consulting charges from Bristol-Myers Squibb; Drs. Tian, Yellin, and Nichol getting former staff of Medarex; Dr. Hoos getting at present employed by Bristol-Myers Squibb with stock or stock selections; and Dr. Urba, getting consulting fees from Bristol-Myers Squibb edarex. No other potential conflicts of interest relevant to this article had been reported. Disclosure types offered by the authors are accessible using the full text of this short article at NEJM.org We thank the individuals who volunteered to participate in this study and staff members at the study web-sites who cared for them; the members on the information and safety monitoring committee; and representatives with the sponsors who had been involved in information collection and analyses (in specific, Tai-Tsang Chen, Xiaoping Zhu, Marianne Messina, and Helena Brett-Smith).Price of 55685-58-0 Editorial and writing help was offered by Ward A. Pedersen of StemScientific, funded by Bristol-Myers Squibb.watermark-text watermark-text watermark-textAPPENDIXThe authors’ affiliations are as follows: The Dana-Farber Cancer Institute (F.S.H.) and Beth Israel Deaconess Medical Center (D.F.M.) — each in Boston; the Angeles Clinic and Study Institute, Los Angeles (S.J.O.); St. Mary’s Healthcare Center, San Francisco (R.W.W.); Vanderbilt University Healthcare Center, Nashville (J.A.S.); Netherlands Cancer Institute (J.B.H.) and VU University Medical Center (A.J.M.E.) — both in Amsterdam; University of Colorado Cancer Center, Aurora (R.G.); Institut Gustave Roussy, Villejuif, France (C.R.); University Hospital Essen, Essen (D.S., J.M.V.), German Cancer Study Center, University of Mannheim, Mannheim (J.C.H.), and Technical University Munich, Munich (C.P.) — all in Germany; Huntsman Cancer Institute, Salt Lake City (W.A.); Mount Sinai Complete Cancer Center, Miami (J.L.); Christie Hospital NHS Trust, Manchester (P.L.), and Southampton University Hospitals, Southampton (C.N-(Chloroacetoxy)succinimide site H.PMID:23800738 O.) — both within the Uk; Washington University School of Medicine, St. Louis (G.P.L.); Princess Margaret Hospital, Toronto (D.H., I.Q.); Saint Louis Hospital, Paris (C.L.); Loyola University Health-related Center, Maywood, IL (J.I.C.); Memorial Sloan-Kettering Cancer Center, New York (J.D.W.); H. Lee Moffitt Cancer Center, Tampa, FL (J.S.W.); Medarex, Bloomsbury, NJ (J.T., M.J.Y., G.M.N.); Bristol-Myers Squibb, Wallingford, CT (A.H.); and the Earle A. Chiles Study Institute, Portland, OR (W.J.U.). As well as the authors, the following investigators (listed by country in alphabetical order) participated within the study: Argentina: M. Chac , L. Koliren, G.L. Lerzo, R.L. Santos — all in Buenos Aires; Belgium: A. Awada (Brussels), V. Cocquyt (Ghent), J. Kerger (Yvoir), J. Thomas (Leuven), T. Velu (Brussels); Brazil: C. Barrios (Porto Alegre), C. Dzik (S Paulo), M. Federico (S Paulo), J. Hohmann.